Sirnaomics Ltd.

Sirnaomics is a clinical-stage RNA therapeutics biopharmaceutical company that is discovering and developing innovative drugs for indications with significant unmet medical needs in areas such as cancers, skin conditions, fibrosis-related diseases, antiviral and cardiometabolic diseases, and medical aesthetics. Founded in 2007 in Gaithersburg, Maryland, and with a presence in Greater China, Sirnaomics has developed proprietary delivery platforms for RNA-based therapeutics, including the polypeptide nanoparticle delivery platform (PNP) for mRNA vaccines and therapeutics, and the GalNAc delivery platform for liver-targeting RNAi therapeutics. The company is also developing various drug candidates like STP705, STP707, STP355, STP369, STP122G, STP125G, STP144G, RV-1730, RV-1770, STP247G, STP145G, STP146G, STP152G, STP136G, STP251G, and STP237G to target different diseases, including oncology, fibrosis, coagulation disorders, hypertriglyceridemia, complement diseases, and hypertension. Sirnaomics has operations in Hong Kong Science Park and is focused on advancing research and development, including a partnership with Gore Range Capital for a joint venture in aesthetic medicine.